Suministro del medicamento exclusivo: Etranacogen Dezaparvovec (HEMGENIX)
TED · 610858-2026Award noticeawardedNo deadline given
Buyer
NameServicio Madrileno de Salud, Hospital Universitario La Paz
CountryES
Published2026-09-04
Deadline—
Who already wins at this buyer
Firms with recorded awards from Servicio Madrileno de Salud, Hospital Universitario La Paz in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ROCHE FARMA, S.A.U. | 2 | €2,779,646 | 2026-06-15 |
| GILEAD SCIENCES, S.L. | 2 | €898,026 | 2026-09-04 |
| BRISTOL-MYERS SQUIBB, S.A.U. | 2 | €824,543 | 2026-06-29 |
| ABBVIE SPAIN, S.L.U. | 2 | €319,559 | 2026-10-01 |
| BIOGEN SPAIN, S.L. | 1 | €2,964,125 | 2026-09-15 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Suministro del medicamento exclusivo: Etranacogen Dezaparvovec (HEMGENIX)
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-09-09 | Suministro del medicamento exclusivo: Ravulizumab (ULTOMIRIS). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 93% |
| 2026-09-04 | Suministro del medicamento exclusivo: Tebentafusp (KIMMTRAK). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 93% |
| 2026-09-18 | Suministro del medicamento exclusivo: Eptacog alfa (NOVOSEVEN). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 93% |
| 2026-09-04 | Suministro de medicamento exclusivo Bulevirtida (HEPCLUDEX) | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 92% |
| 2026-09-10 | Suministro del medicamento exclusivo: Factor IX Recombinante-Eftrenonacog Alfa (ALPROLIX). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 92% |
| 2026-05-05 | Suministro de medicamento exclusivo: Epcoritamab (TEPKINLY). | Servicio Madrileno de Salud, Hospital Universitario La Paz ES | 92% |